Description:

InChiKey:
XVPBINOPNYFXID-ACTGZQEFSA-N

Description:
Distinguishes between live vs dead cells in a single reagent. The NUCLEAR-ID® Blue/Green cell viability reagent is a mixture of a blue fluorescent cell-permeable nucleic acid dye and a green fluorescent cell-impermeable nucleic acid dye that is suited for staining dead nuclei. The staining pattern arising from the simultaneous combination of these two dyes permits determination of live and dead cell populations by fluorescence/confocal microscopy. The reagent, supplied as a 1000x solution, is sufficient for 1000 microscopy assays. The single-tube format makes this cell viability reagent easy to use. It leaves the cytoplasm unstained, potentially allowing visualization of other cell markers.{{1801765-04-7} MedChemExpress|{1801765-04-7} Purity & Documentation|{1801765-04-7} Formula|{1801765-04-7} manufacturer} Figure 1: The NUCLEAR-ID® Blue/Green dye is detected as blue-stained nuclei in live cells and fluorescent-green nuclei in dead cells (arrows).{{1124329-14-1} web|{1124329-14-1} Protocol|{1124329-14-1} In Vitro|{1124329-14-1} manufacturer} Figure 1: The NUCLEAR-ID® Blue/Green dye is detected as blue-stained nuclei in live cells and fluorescent-green nuclei in dead cells (arrows).PMID:25905396

Description:

InChiKey:
BVUJISIVAHYNLI-FIBGUPNXSA-N

Description:
Dihydrofolate reductase inhibitor Folic acid antagonist. Potent inhibitor of dihydrofolate reductase.{{1393477-72-9} site|{1393477-72-9} Protocol|{1393477-72-9} References|{1393477-72-9} supplier} Induces apoptosis. Inhibits DNA synthesis. Anticancer agent.

Description:
A QUANTIZYME® Assay System. The MMP-13 Colorimetric Drug Discovery Kit is a complete assay system designed to screen inhibitors of matrix metalloproteinase-13 (MMP-13, collagenase-3) using a thiopeptide as a chromogenic substrate. The assays are performed in a convenient 96-well microplate format. Included are active enzyme, assay buffer, a prototypic control inhibitor (NNGH), and a detailed instruction booklet.

InChiKey:
DRXHAKVGNKHFMB-UHFFFAOYSA-N

Description:
The lymphocyte activation gene-3 (LAG-3, CD223), a member of the immunoglobulin superfamily (IgSF) related to CD4, binds to the major histocompatibility complex (MHC) class II molecules but with higher affinity than CD4.{{1774353-12-6} MedChemExpress|{1774353-12-6} Technical Information|{1774353-12-6} Description|{1774353-12-6} manufacturer} Several alternative mRNA splice-variants of human LAG-3 have been described, two of them encoding potential secreted forms: LAG-3V1 (i.{{945604-76-2} site|{945604-76-2} Purity & Documentation|{945604-76-2} Formula|{945604-76-2} supplier} e. the D1-D2 domains of the protein, 36 kDa) and LAG-3V3 (D1-D3, 52 kDa). The longer form was detected by ELISA in the serum of healthy individuals as well as of tuberculosis patients with a favorable outcome. LAG-3 expression by T cell clones correlated with IFN-γ production, and hence soluble LAG-3 has been suggested as a serological marker of Th1 responses. Western blot analysis of LAG-3 mAb (L4-PL33) : Lane 1: MW marker, Lane 2: LAG-3 (human):Fc (human), (recombinant) . Immunohistochemistry analysis of formalin-fixed, paraffin-embedded human tonsil tissue stained with LAG-3 (human) recombinant mAb (L4-PL33) at 6μg/ml. Flow cytometry analysis of 0.5×10^6 THP-1 cells stained using LAG-3 mAb (L4-PL33) at a concentration of 5μg/ml, followed by Alexa Fluor® 488 conjugated anti-mouse secondary antibody. Western blot analysis of LAG-3 mAb (L4-PL33) : Lane 1: MW marker, Lane 2: LAG-3 (human):Fc (human), (recombinant) . Immunohistochemistry analysis of formalin-fixed, paraffin-embedded human tonsil tissue stained with LAG-3 (human) recombinant mAb (L4-PL33) at 6μg/ml. Flow cytometry analysis of 0.5×10^6 THP-1 cells stained using LAG-3 mAb (L4-PL33) at a concentration of 5μg/ml, followed by Alexa Fluor® 488 conjugated anti-mouse secondary antibody.

Description:
The Hsp90 family of heat shock proteins represents one of the most abundantly expressed and highly conserved families of cellular chaperones whose expression can be upregulated under conditions of cellular stress, and includes cytoplasmic (Hsp90-alpha/beta), ER (grp94), and mitochondrial (TRAP1) localized members. Structurally, Hsp90 is characterized by an N-terminal ATP-binding domain, a medial substrate-binding domain, and a C-terminal dimerization motif. Hsp90 dimers function in cooperation with cochaperones (e.g. Hsp40, Hsp70, Hop, p23) to stabilize a multitude of client protein substrates, including steroid hormone receptors, protein kinases, and transcription factors. The essential binding and hydrolysis of ATP by Hsp90 is inhibited by ansamycin drugs (e.g. geldanamycin, 17-AAG) which occupy the N-terminal Hsp90 nucleotide-binding pocket. Many Hsp90 client proteins such as erbB2/Her-2, c-raf, bcr-abl, p53, and hTERT, are members of well characterized oncogenic pathways, making Hsp90 inhibitors useful anticancer agents. Immunohistochemistry analysis of human breast cancer tissue using Hsp90β mAb (K3705). Western blot analysis of HSP90β: Lane 1: MW marker, Lane 2: HSP90 Native Human Protein, Lane 3: HSP90α Recombinant Human Protein, Lane 4: HSP90β Recombinant Human Protein, Lane 5: HeLa, Lane 6: PC-12, Lane 7: CHO-K1, Lane 8: 3T3.{{2173054-79-8} site|{2173054-79-8} Purity & Documentation|{2173054-79-8} In Vitro|{2173054-79-8} manufacturer} Immunohistochemistry analysis of human breast cancer tissue using Hsp90β mAb (K3705). Western blot analysis of HSP90β: Lane 1: MW marker, Lane 2: HSP90 Native Human Protein, Lane 3: HSP90α Recombinant Human Protein, Lane 4: HSP90β Recombinant Human Protein, Lane 5: HeLa, Lane 6: PC-12, Lane 7: CHO-K1, Lane 8: 3T3.{{1900754-56-4} medchemexpress|{1900754-56-4} Technical Information|{1900754-56-4} Formula|{1900754-56-4} custom synthesis}